Citadel Advisors’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Citadel Advisors’s Portfolio KRSA Stock Details KRSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$203K	Buy	8,542 +5,933	+227%	+$19.3K	﹤0.01%	12043
2026 Q1	$28K	Buy	+2,609	New	+$3.71K	﹤0.01%	12592
2022 Q4	–	Sell	-76	Closed	-$6.3K	–	14932
2022 Q3	$9K	Buy	+76	New	+$1.31K	﹤0.01%	12293
2022 Q1	–	Sell	-665	Closed	-$112K	–	13733
2021 Q4	$160K	Buy	665 +141	+27%	+$6.66K	﹤0.01%	12181
2021 Q3	$225K	Sell	524 -121	-19%	-$7.92K	﹤0.01%	11726
2021 Q2	$352K	Buy	645 +543	+532%	+$34K	﹤0.01%	10875
2021 Q1	$40K	Buy	+102	New	+$7.66K	﹤0.01%	12978
2019 Q4	–	Sell	-1,674	Closed	-$2.84M	–	9205
2019 Q3	$2.84M	Sell	1,674 -458	-21%	-$98.9K	﹤0.01%	3941
2019 Q2	$3.42M	Buy	+2,132	New	+$603K	﹤0.01%	3654

Other funds holding KRSA

KCM

Kalehua Capital Management Dallas, Texas $174M AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors's KRSA Position: Q2 2026 in Review

Citadel Advisors increased its Korsana Biosciences, Inc. Common Stock (KRSA) stake by 227% in Q2 2026, buying an estimated $19.3K and bringing the position to 8,542 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #12043.

Citadel Advisors first reported a position in KRSA in Q2 2019 and has held it in 9 quarters since. The position peaked at $3.42M in Q2 2019. 21 funds tracked by Wall St. Rank hold KRSA as of Q2 2026.

Citadel Advisors held 8,542 shares of Korsana Biosciences, Inc. Common Stock worth $203K as of Q2 2026.
Citadel Advisors bought 5,933 Korsana Biosciences, Inc. Common Stock shares in Q2 2026, an estimated $19.3K.
Korsana Biosciences, Inc. Common Stock made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12043 holding.
Citadel Advisors first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and has held it in 9 quarters since.
Citadel Advisors's Korsana Biosciences, Inc. Common Stock position peaked at $3.42M in Q2 2019.
21 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.